Bonesupport and Orthocell Collaborate to Create Bone Repair Product

Bonesupport AB and Orthocell Pty Ltd. are collaborating to co-develop bone repair products based on the existing technologies of each company. The eluting bone remodeling capabilities of Bonesupport’s injectable bone graft product Cerament is hoped to be combined with the collagen properties of Orthocell’s Celgro, a bone growth product based on a stem cell platform.

The two companies will join to advance the development of Celgro, which has dual purposes: The product acts as a delivery system for the patient’s cultured cells which are seeded into the collagen matrix; and it provides biomechanical support and stabilization to the damaged tissue. The companies have agreed to work together to incorporate Celgro into Cerament to create a bone repair product that will not only support the damaged bone, but induce the superior growth of new bone matrix.

Cerament is meant for use in orthopedic trauma, bone infection and instrumentation augmentation and is currently marketed in the United States and Europe. It mimics human bone and provides short-term support for the fracture or bone void with pain relief and stabilization, while providing longer term support which enhances new bone growth. The product’s biologic properties come in a ready-to-use formulation and features drug eluting capabilities, which makes it attractive for combination with substances such as collagen.

One of the key goals of bone repair is to induce new growth of bone matrix. Bone induction matrix formation in turn relies on the incorporation of complex growth factor and collagen interactions, which are not provided by synthetic bone repair products. The Celgro collagen scaffold is being positioned as a solution to this problem, and Cerament will take the role of the platform to facilitate delivery.


“This is an exciting step forward for both companies and further validates Celgro as a platform technology that can be used in varying surgical specialities. Bonesupport offers market leading products for bone void filling and regeneration and its agreement with Orthocell is a significant external validation of the potential of Celgro in a variety of surgical applications.” said Paul Anderson, managing director of Orthocell.

“We are pleased to partner with Orthocell to advance bone healing,” said Lloyd Diamond, CEO of Bonesupport. “We believe combining the important collagen properties of Orthocell’s Celgro and the proven remodelling and eluting capabilities of Cerament will enable us to develop novel regenerative technologies and treatments to further bone regeneration.”

Bonesupport makes injectable osteoconductive biomaterials for the treatment of fragility fractures and bone voids based in Lund, Sweden.

Orthocell is a regenerative medicine company focused on soft tissue injuries and subsequent chronic musculoskeletal disorders based in Murdoch, Australia.